Introduction Sleep and epilepsy have an established bidirectional relationship yet only one randomised controlled clinical trial has assessed the effectiveness of behavioural sleep interventions for children with epilepsy. The intervention was successful, but was delivered via face-to-face educational sessions with parents, which are costly and non-scalable to population level. The Changing Agendas on Sleep, Treatment and Learning in Epilepsy (CASTLE) Sleep-E trial addresses this problem by comparing clinical and cost-effectiveness in children with Rolandic epilepsy between standard care (SC) and SC augmented with a novel, tailored parent-led CASTLE Online Sleep Intervention (COSI) that incorporates evidence-based behavioural components.
Methods and analyses CASTLE Sleep-E is a UK-based, multicentre, open-label, active concurrent control, randomised, parallel-group, pragmatic superiority trial. A total of 110 children with Rolandic epilepsy will be recruited in outpatient clinics and allocated 1:1 to SC or SC augmented with COSI (SC+COSI). Primary clinical outcome is parent-reported sleep problem score (Children’s Sleep Habits Questionnaire). Primary health economic outcome is the incremental cost-effectiveness ratio (National Health Service and Personal Social Services perspective, Child Health Utility 9D Instrument). Parents and children (≥7 years) can opt into qualitative interviews and activities to share their experiences and perceptions of trial participation and managing sleep with Rolandic epilepsy.
Ethics and dissemination The CASTLE Sleep-E protocol was approved by the Health Research Authority East Midlands (HRA)–Nottingham 1 Research Ethics Committee (reference: 21/EM/0205). Trial results will be disseminated to scientific audiences, families, professional groups, managers, commissioners and policymakers. Pseudo-anonymised individual patient data will be made available after dissemination on reasonable request.
Trial registration number ISRCTN13202325.
- Paediatric neurology
- SLEEP MEDICINE
- Clinical trials
- QUALITATIVE RESEARCH
This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
STRENGTHS AND LIMITATIONS OF THIS STUDY
First randomised controlled trial to evaluate the clinical and cost-effectiveness of a novel, tailored, parent-led Changing Agendas on Sleep, Treatment and Learning in Epilepsy (CASTLE) Online Sleep Intervention (COSI) that incorporates evidence-based behavioural components for children with Rolandic epilepsy.
Extensive patient and public involvement via dedicated CASTLE Advisory Panel.
Embedded health economic evaluation.
Heavily reliant on parent and child self-report to assess intervention implementation, ameliorated by COSI e-analytics and actigraphy data.
Epilepsy is one of the most common long-term neurological conditions worldwide whose prevalence peaks during childhood (5–9 years) and later in life (over 80 years).1 Epilepsy in children (5–<13 years) accounts for the annual loss of 2.6 million disability-adjusted life years, equivalent to 1.8% of the global burden of disease among children and adolescents.2 Rolandic epilepsy (RE) is the most common childhood epilepsy.3
In the UK, RE has a stable crude incidence rate of 5 in 100 000 children (<16 years) or 542 new cases annually.4 Concurrent neurodevelopmental disorders are very common (35%).5 Seizures are often triggered by sleep fragmentation.6 Many parents co-sleep or monitor children with nocturnal seizures, and children experience a fear of death during and after a seizure.7 Problems related to sleep emerge as a top concern for both children and parents,8 but are often unaddressed.9 10
A recent systematic review and meta-analysis of clinical trials shows that parent-based behavioural sleep interventions are effective for typically developing children and those with neurological and neurodevelopmental disorders.10 The review concluded that randomised controlled clinical trials assessing functional outcomes (eg, cognition, emotion, behaviour) and targeting specific populations (eg, epilepsy) are missing (but see two recent trials).11 12 Harms capture for cognitive–behavioural and behavioural sleep interventions has been sparse (only 32.3% of trials address adverse events (AEs)) and predominantly inadequate (92.9% of trials do not meet adequate reporting criteria).13 Observed harms of behavioural sleep interventions in adults have been mild (eg, transient fatigue/exhaustion from sleep restriction in insomnia in 25%–33% of participants).14 The only published paediatric and adult epilepsy trials did not address harms.11 12 Based on the existing evidence, the benefits of behavioural sleep interventions in children with epilepsy outweigh potential harms, especially because sleep problems not only affect seizure control, but overall child well-being, learning and memory, and parental quality of life.9 10 There remains, however, uncertainty whether sleep interventions, which can be resource intensive, are cost-effective in public health systems.
This protocol describes the design for the Changing Agendas on Sleep, Treatment and Learning in Epilepsy (CASTLE) Sleep-E trial, which evaluates the clinical and cost-effectiveness of a novel, tailored, parent-led CASTLE Online Sleep Intervention (COSI) that incorporates evidence-based behavioural components for children with epilepsy. COSI and CASTLE Sleep-E outcome selections were co-produced by affected children, young people and their parents, sleep and epilepsy experts.8 15–17 The CASTLE Sleep-E protocol follows Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT),18 19 its extension for Patient-Reported Outcomes,20 and the Guidance for Reporting Involvement of Patients and the Public (GRIPP2).21
As CASTLE Sleep-E is a pragmatic superiority trial assessing whether UK standard care (SC) for children with RE should be augmented with an online behavioural sleep intervention, SC is the appropriate comparator.22–24 Current UK clinical guidelines25–27 recommend that SC for children with RE consists of a comprehensive care plan with the option of pharmacological treatment with anti-epileptic drugs (AEDs).
The primary objective of CASTLE Sleep-E is to determine if SC augmented with COSI is superior to SC alone in reducing sleep problems in children with RE and cost-effective. Implementation details and secondary objectives are reported in table 1.
Methods and analyses
CASTLE Sleep-E is a UK-based, multicentre, open-label, active concurrent control, randomised (1:1), parallel-group, pragmatic superiority trial (overall trial start date: 14 May 2018, first trial site opened: 12 May 2022, first recruitment: 30 August 2022, planned trial end date: 31 July 2023). Compared are clinical and cost-effectiveness of SC alone and SC augmented with a novel, tailored, parent-led COSI (SC+COSI) in reducing sleep problems in children (5–<13 years) with RE at 3 and 6 months after randomisation. Parents and children (≥7 years) can opt into qualitative interviews and activities to share their experiences and perceptions within 3 weeks of completion of other data collection at 3 and 6 months after randomisation.
Patient and public involvement
The CASTLE Programme (which subsumes CASTLE Sleep-E) recruited a dedicated patient and public involvement (PPI) Advisory Panel (AP) through social media and epilepsy charities in 2017. The CASTLE AP (CAP) consists of 17 adults with experience of childhood epilepsy and 5 children with epilepsy (aged 6–15 years). CAP has been involved in CASTLE from the funding application onward (two CAP members are co-applicants). Full PPI details are provided in GRIPP2-Short Form in table 2.
Trial setting and eligibility criteria
Participants will be identified by staff in National Health Service (NHS) outpatient general paediatric and paediatric epilepsy clinics in the UK (predominantly urban setting). Eligibility criteria for participants are reported in online supplemental table 1, field 14 of the WHO Trial Registration Data Set (V.1.3.1). In the UK, a clinical RE diagnosis is based on electroclinical criteria defined by the International League Against Epilepsy (https://www.ilae.org/). Semiology and electroencephalogram (EEG) need to be judged as concordant by a consultant neurophysiologist. Neuroimaging does not form part of UK SC for RE. Eligibility criteria for trial sites include a capacity and capability assessment as advised for NHS site set-up by the UK Health Research Authority (HRA). The expected number of trial sites is 40 (England: 34, Scotland: 4, Wales: 1, Northern Ireland: 1). A list of trial sites can be obtained from the trial manager (see online supplemental table 1).
Participants will be allocated to trial arms (SC or SC+COSI) using minimisation (1:1 ratio). On allocation to SC+COSI, participants will receive an email with access details to COSI. COSI consists of a self-paced, novel, tailored, e-learning package for parents of children with epilepsy that incorporates evidence-based behavioural components. Table 3 provides a brief overview; detailed reports on the development, content and evaluation of COSI have been published.15 16 COSI is divided into 13 modules (1 screening for child-specific sleep problems to allow tailoring, 10 content, 1 additional resources, 1 initially hidden evaluation), of which 3 are compulsory (1 screening, 2 content). The non-compulsory modules are recommended based on screening outcome, but all modules are accessible, repeatable and printable. The advice in COSI supports parents to implement general prevention techniques (eg, good sleep hygiene) and specific behavioural change techniques (eg, bedtime fading) relevant to their child’s sleep problems. Three months after first being given access to COSI, parents will be asked by email to complete a COSI evaluation module. At the end of a participant’s trial timeline (6 months), access to COSI will be revoked. After the trial, all families (irrespective of trial allocation) have the option to receive the COSI content in electronic format via email.
Fidelity, adherence, retention and acceptability
Fidelity (intervention delivery) will be monitored through e-analytics embedded in the COSI system (modules accessed and time spent per module). Strategies to improve completion of COSI training in case of non-access include: (1) an automated text reminder after 2 days; (2) an email reminder after 4 days; (3) a phone call from researchers who developed COSI (the Sleep Team) after 6 days. To improve adherence to the intervention, (1) all participants will receive a phone call from the Sleep Team 6 weeks after account creation; and (2) children will receive postcards with child-oriented activities (eg, maze) at three time points to welcome them to the trial (weeks 1–2), to stay in touch (weeks 4–5) and to thank them for participating (weeks 4–8 post-trial). To encourage completion of the intervention evaluation, participants will receive: (1) an automated text reminder after 3 days of non-completion, (2) and a phone call from the Sleep Team after 8 days of non-completion. Fidelity (intervention implementation, acceptability, perceived helpfulness) will be captured jointly by the COSI evaluation module and the qualitative trial component.
Discontinuation, withdrawal, concomitant care or interventions
Participants may discontinue the trial intervention or withdraw from the trial if (1) the parent/child withdraws consent/assent, respectively; or (2) a change in the child’s condition justifies discontinuation of treatment in their clinician’s opinion. Trial site staff will record withdrawal with reason where provided in electronic Case Report Forms (eCRFs). Pseudo-anonymised data up to the time of consent withdrawal will be included in analyses in accordance with General Data Protection Regulation (GDPR)28 under the UK Data Protection Act 201829—the trial data controller relies on the legal bases of ‘public interest’ and ‘research purposes’.
To avoid confounding and to minimise participant burden, co-enrolment into other clinical trials is discouraged. Where recruitment into another trial is considered appropriate, the trial coordinating centre will discuss enrolment with the chief investigator (CI). Participation in the Rolandic Epilepsy Genomewide Association International Study (https://childhoodepilepsy.org/research-studies/regain/) is complementary (same CI).
Outcomes and participant timeline
Outcomes are reported in table 1 and were chosen collaboratively by children and young people with epilepsy and their parents, sleep and epilepsy experts8 17 in accordance with Core Outcome Measures in Effectiveness Trials guidelines.30 Psychometric properties and clinical relevance of outcomes are reported in online supplemental table 3. Each participant will be followed up for 6 months. The participant timeline and estimated time requirement are, respectively, shown in table 4 and online supplemental table 4.
The target sample size (110 children with RE, 55 per trial arm) was calculated based on achieving 90% power to detect the minimal clinically important difference (MCID) in the primary clinical outcome (Children’s Sleep Habits Questionnaire (CSHQ)) at 3 months after randomisation, accounting for 10% expected attrition (non-parametric test with two-sided 5% significance level). MCID was defined based on an individual-focused anchor-based method,31 that is, ‘the smallest difference in outcome that patients perceive as beneficial and which mandates a change in patient management’.32 The MCID value was based on the estimated reduction in total CSHQ score required for children with epilepsy (M=48.25, SD=8.91)7 to fall at or below the diagnostic cut-off score of 41 for sleep disorders in paediatric populations.33
Recruitment, stopping guidelines and interim analyses
An Independent Data and Safety Monitoring Committee will monitor recruitment and make recommendations to the Trial Steering Committee (TSC) concerning trial continuation, adjustments of recruitment methods and follow-up optimisation (see online supplemental table 2). A traffic light approach will determine trial continuation: (1) green: continue if at least 30 trial sites have opened and 22 participants have been randomised by end of month 6; (2) amber: implement additional recruitment strategies if 15–21 participants have been randomised by end of month 6; (3) red: if recruitment is <15 participants by end of month 6, then stopping the trial early will be discussed with the TSC. Formal interim analyses of the accumulating data will not be performed.
Participants will be allocated with a 1:1 ratio to either SC or SC+COSI based on a computer-generated adaptive restricted randomisation procedure that minimises differences between trial arms in variables likely to affect outcomes. Minimisation algorithm details are not published to avoid subversion of allocation sequence concealment, but include seizure frequency, AED and sleep medication details. The allocation concealment mechanism is an online, central randomisation service implemented and maintained by the Liverpool Clinical Trial Centre (LCTC). The service will be accessed within 4 weeks of participant enrolment (once consent and eligibility confirmed, participant ID issued, baseline dataset completed) by trained, authorised staff at trial sites. Randomisation will trigger allocation emails to the trial manager at LCTC and to the relevant trial site as well as enable COSI access for participants allocated to the intervention arm. Trial sites will notify the participant’s general practitioner of the treatment allocation by letter (electronic or hard copy, depending on preference).
Only quantitative data analysts will be blinded (participant IDs do not reveal treatment allocation). All other stakeholders (participants, parents, healthcare providers, data collectors, qualitative researchers) will be aware of the allocated intervention. Emergency unblinding procedures are therefore unnecessary.
Assent and consent
Potentially eligible children will be screened at trial centres by trained site staff. Screening outcome will be documented. Eligible children with interested parents will be invited to participate and provided with a Patient Information Sheet and Consent (PISC) Form electronically and/or hard copy (PISC, three versions: parent, child (5–6 and 7–12 years)). Sufficient time will be allowed for discussion of the trial and the decision to assent/consent to trial entry and the optional qualitative component. Assent (children aged 7–12 years) and consent (parents) may be given face-to-face or remotely and will be electronically captured in a secure Consent Database managed by LCTC. Reasons for declining participation will be asked, but it will be made clear that children and parents do not have to provide a reason.
Data collection and management
Data collection will be carried out electronically except for Serious Adverse Events and Participant Transfer Forms (hard copy). At consent/assent, site staff will enter patient medical history (including EEG), eligibility confirmation, COVID-19 screening and demographics (see table 4) into eCRFs stored in a secure Data Management System managed by LCTC. Trial participation will be added to the patient’s medical records alongside their unique participant ID.
Consent and Contacts Databases are securely linked. The addition of a new participant will trigger email notifications to the parents containing access links to baseline assessments (see table 4) and the Sleep Team who will access the Contacts Database to arrange the delivery of an iPad preconfigured by LCTC (optionally fitted with prepaid SIMs), and two actigraphs with supporting documents. iPads (Generations 7–8, iOS V.15.2 or V.15.3) will be used to access the SleepSuite App (V.1.4),34 which assesses executive functions in child-friendly, interactive games (eg, popping virtual bubbles with smiling children’s faces). Access requires the participant ID and is only possible at prespecified trial time points (see table 4). Data are only stored on the iPad until the test session completion, then automatically uploaded to a cloud-based server, and then securely downloaded for analyses by authorised LCTC staff. Families lacking other means of internet access can use iPads fitted with prepaid SIMs to access other online trial materials (including email).
Actigraphs (Micro Motionlogger Watch and Watchware Software V.184.108.40.206, Ambulatory Monitoring, New York, USA) will be used to collect 14 days of objective sleep data from child and parent. Concurrent sleep diaries (hard copies) will be completed by the parent with or without child input. At the end of the baseline period, actigraphs will be returned to the Sleep Team via prepaid courier. The Sleep Team will download and securely store pseudo-anonymised (using participant IDs) actigraphy data for pre-processing (manual selection of sleep periods cross-checked against sleep diaries) per night at participant level. Summary variables (sleep latency, total sleep time and sleep efficiency) are then automatically calculated by actigraph software, manually collated and securely transferred electronically to LCTC for trial-level analyses by the trial statistician.
Participants will be randomised to trial arms during a telephone/video call or clinic visit only after site staff have confirmed that baseline data (see table 4) are complete, and eligibility, consent/assent and contact details are still valid. Data collection will be repeated 3 and 6 months after randomisation, and iPads to LCTC via trial sites (see table 4).
The Qualitative Research Team will access the Contacts Database to schedule audio-recorded interviews with children and parents who consented/assented to this optional trial component. Interviews (audio or audio-video) will take place remotely within 3 weeks of completion of other data collection at 3 and 6 months after randomisation. Parents and children will be interviewed together or separately as preferred. Parents and children will have the opportunity to think through their ideas prior to the interview (as proposed by parents and children from the CAP). Children will be invited to complete activity booklets in advance of their interviews (the booklets will be mailed or emailed 1 week prior to their interview); the content they complete will support the interview. Parents will receive a list of proposed questions/topics. Children will be able to share the booklet with the Qualitative Team (eg, screen or photograph sharing, verbal description).
The direct costs of health and personal social services, and indirect costs of productivity losses and school absenteeism will be collected using a Resource Use Questionnaire administered at baseline and during follow-up visits. Other data such as concomitant medications, study visits and AEs will be collected using eCRFs. Trial participants’ use of secondary care services will be collected from Patient-Level Information and Costing Systems (PLICS) data obtained from the finance departments of each recruiting hospital or from Hospital Episode Statistics (HES) data obtained from NHS Digital at the end of the trial. PLICS and HES data will be pseudo-anonymised and transferred securely to the trial health economists at Bangor University.
Data quality, security and trial oversight
Reliability, validity and clinical relevance of outcomes are reported in online supplemental table 3. Processes to promote quality and security of collected data include general local training of site staff and research teams (Good Clinical Practice), and trial-specific training in the use of electronic forms and databases by LCTC. LCTC will request to see evidence of appropriate training and experience of all trial staff. Staff will be signed off as appropriately qualified by the CI. Electronic data capture provides several in-built validity and security checks (eg, data type, range and missingness checks in eCRFs, SleepSuite use/access restrictions). Some electronic and all hard copy data will be repeat checked (eg, eligibility, contact details). Data processing requiring more subjective judgement will be performed by minimum of two trained researchers on at least a subset of data (ie, manually assisted selection of actigraphy sleep period; thematic and content analysis of qualitative data).
Data will be processed and stored in accordance with GDPR under the UK Data Protection Act 2018. Central data monitoring will be performed by LCTC which will raise and resolve queries with site and research teams within the online system. The University of Liverpool is registered with the Information Commissioners Office. LCTC will receive trial participants’ HES identifiers for secure transfer to the Health Economic Team, who will access, securely store and dispose of HES data in accordance with the Bangor University and NHS Digital Data Sharing Framework Contract.
Statistical analyses of all but health economic and qualitative data will be performed by the trial statistician (LCTC) using SAS software, V.9.4 or later. Intention-to-treat will be the main analysis strategy for primary and secondary outcomes (see table 1 and table 5). Minimisation variables (including seizure frequency, AED and sleep medication details) will be adjusted for at baseline. Statistical significance will be set at the conventional two-sided 5% level; clinical relevance will be based on previous research (see online supplemental table 3). Point estimates with 95% two-sided CIs will be reported adjusted and unadjusted for covariates. No multiplicity adjustments will be made (only one primary clinical outcome, uncorrected secondary outcome analyses).
Sensitivity analyses will be carried out if the amount of missing data is greater than 10%. Multiple imputation will be used to assess the robustness of the analysis to missing primary outcome data. The multiple imputation method will follow published guidelines.35 PROC MI in SAS (version 9.4 or later) will be used to generate 50 complete datasets. The imputation model will include all variables included in the primary outcome analysis model. The overall summary adjusted mean difference will be presented with 95% CIs, to assess the sensitivity of the primary analysis to missing data. All analyses will be reported in accordance with the Consolidated Standards of Reporting Trials Checklist36 and regardless of statistical significance.
Health economic evaluation
The economic analysis will be performed in accordance with a Health Economics Analysis Plan, and by the trial health economists at Bangor University. The primary analysis will adopt an NHS and Personal Social Services perspective and, based on quality-adjusted life years (QALYs) as a measure of health outcome, estimate the incremental cost-effectiveness ratio from an incremental analysis of the mean costs and QALYs for the intervention and control trial arms.37 Data assumed to be missing at random will be imputed using multiple imputation by chained equations.38
Sensitivity analyses will be conducted to test whether, and to what extent, the incremental cost-effectiveness ratio is sensitive to key assumptions in the analysis (eg, unit prices, different utility estimates from Child Health Utility Index 9D39 vs EQ-5D-Y40). The joint uncertainty in costs and QALYs will be addressed through application of bootstrapping and estimation of cost-effectiveness acceptability curves.41 Alternative scenarios considering a broader cost perspective (including indirect costs, such as school absences and loss of productivity, valued by reference to published sources) and a range of outcomes (including parental QALYs, measured using the EQ-5D-5L42 and Insomnia Severity Index43 44) will be conducted. Inclusion of spillover disutility45 (impact on parents’ utility) will be based on the National Institute for Health and Care Excellence reference case specification46 that all QALYs are of equal weight and calculated assuming additive effects. Health economic findings will be reported according to the Consolidated Health Economic Evaluation Reporting Standards.47
Child and parent interviews will be analysed by the Qualitative Research Team using an interpretive, reflexive and conceptual analytical approach. Audio-recordings of interviews will be transcribed and thematically analysed in discrete sets (eg, intervention/control, child/parent, engagement/lack of engagement with intervention, types of decision-making, different responses/experiences). Parent and child transcripts will first be analysed separately, and then as dyads. All data will be used for synthesis. Thematic and content analyses will be used for child activity booklets (text and images). Qualitative and selected quantitative data (eg, anxiety measures, actigraphy data) will be compared, as appropriate.
A flow chart of AE-reporting requirements is shown in online supplemental figure 1. Harms severity and causality will be graded by the investigator responsible for the care of the participant based on categories shown in online supplemental table 5. If any doubt about causality exists, the local investigator should inform LCTC who will notify the CI. In case of discrepant views, the Research Ethics Committee (REC) will be informed of both views. Seriousness and expectedness of AEs will be defined based on International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Definitions and Standards for Expedited Reporting (ICH E2A, ref: CPMP/ICH/377/95). Expectedness will be assessed by the CI. The only expected AEs in CASTLE Sleep-E are mild and transient worsening of sleep behaviours targeted by the trial intervention. Safety data will be quality checked by a statistician not otherwise involved in the trial. Safety analysis will include all patients randomised and starting treatment and be presented descriptively split by treatment arm.
The CI will ensure that the trial team conducts monitoring activities of sufficient quality and quantity (eg, protocol adherence, consent/assent, data quality). The sponsor will delegate monitoring duties and activities to LCTC. The CI and LCTC will inform the sponsor of any concerns. Auditing does not meet the National Institute for Health and Care Research or SPIRIT statement definitions of independence19 48 as auditors (LCTC and CI) are part of the trial team.
Substantive protocol amendments will be notified to HRA via the UK’s Integrated Research Application System. Trial sites will receive an amendment pack of HRA-approved and REC-approved changes and unless an objection is received within 35 days, the trial will continue at site with a GO LIVE email.
Ancillary and post-trial care
King’s College London (KCL) holds insurance against claims from participants for harm caused by their participation in this clinical study; compensation can be claimed in case of KCL negligence.
Ethics and dissemination
The CASTLE Sleep-E protocol was approved by the HRA East Midlands–Nottingham 1 REC (reference: 21/EM/0205). Trial results will be disseminated to scientific audiences in peer-reviewed publications and conferences, and—with the help of the CAP (parent and child experts by experience), relevant charities (eg, Epilepsy Action, Epilepsy Society and Cerebra) and professional groups (eg, Royal College of Paediatrics and Child Health, Epilepsy Specialist Nurses Association)—as plain language summaries to families, other professional groups, managers, commissioners and policymakers. Pseudo-anonymised individual patient data and associated documentation (eg, protocol, statistical analysis plan, annotated blank CRF) will be made available after dissemination on reasonable request.
Patient consent for publication
Twitter @CarterBernie, @hollycrudge, @kcd_neuro, @HughesDyfrig, @AliRouncefield, @DrHolly_Saron, @palneurolab
Collaborators Nadia Al-Najjar, Lucy Bray, Bernie Carter, CAP, Amber Collingwood, Georgia Cook, Holly Crudgington, Jant Currier, Kristina C Dietz, Will A S Hardy, Harriet Hiscock, Dyfrig Hughes, Christopher Morris, Deborah Roberts, Alison Rouncefield-Swales, Holly Saron, Catherine Spowart, Lucy Stibbs-Eaton, Catrin Tudur Smith, Victoria Watson, Liam Whittle, Luci Wiggs, Eifiona Wood, Paul Gringras, Deb K Pal. CASTLE Advisory Panel (CAP): Steve Carr, Alisa Carr, Charlotte Carr, James Carr, Matthew Carr, Keith Hardy, Ned Hardy, Tim Ingram, Clare Ingram, Oliver Ingram, Rachael Martin, Charlotte Myer, Beccy Pile, Kelly Reynolds, Deborah Roberts, Rachel Roberts, Caris Stoller, Caroline Towell, Bethany Towell.
Contributors PG and DKP (chief investigators), CT-S, DR, HH, JC, LW, BC, CM, DAH and LB (co-investigators) conceived the study and are award holders. Topic expertise for the core outcome set development was provided by CAP, LB, BC, AC, HC, PG, DAH, CM, DKP, and CT-S. Epilepsy expertise by experience was provided by CAP. Topic expertise for epilepsy was provided by DKP. Topic expertise for the health economic evaluation was provided by WASH, DAH and EW. Topic expertise for intervention development was provided by GC, PG, HH, DKP and LW. Topic expertise for patient and public involvement (Advisory Panel and Family Engagement) was provided by CAP, AR-S, LB, BC and CM. Responsibility for the selection of patient-reported outcomes lay with CM. Responsibility for programme management lay with AC. Topic expertise for qualitative research components was provided by CAP, LB, BC and HS. Topic expertise for sleep was provided by GC, PG, HH and LW. Topic expertise for statistical analyses was provided by CT-S, VW and LWh. Responsibility for trial management lay with NA‑N, CS and LS-E. All authors contributed to the design and refinement of the study protocol. The protocol manuscript was written by KCD (including supplemental materials but excluding figure 1 and Patient Information Sheet and Consent Forms). Authors in the Trial Management Group (TMG) had the opportunity to provide feedback twice (initial and final draft); non-TMG authors had the opportunity to provide feedback once (final draft). Provided feedback was incorporated. The final manuscript was approved for publication by all authors. GRIPP2 content was checked for accuracy by LB. Sponsor name and contact information are provided in online supplemental table 1. Details of trial committees and other groups and individuals overseeing the trial are listed in online supplemental table 2. Trial site principal investigators will be listed alphabetically in publications of trial results as members of the CASTLE Sleep-E Consortium in the Acknowledgements section. There has not been and will not be any use of hired writers.
Funding This work is supported by the National Institute for Health and Care Research (NIHR) (award number RP-PG-0615-20007). HH was supported by a National Health and Medical Research Council (NHMRC, Australia) Practitioner Fellowship (1136222). HH’s institute—the Murdoch Children's Research Institute (MCRI, Australia)—is supported by the Victorian Government’s Operational Infrastructure Support Program (no award/grant number).
Competing interests None declared.
Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.